SCHEDULE 13G/A: Morgan Stanley Amends Stake in Arbutus Biopharma, Disclosing 11.4% Beneficial Ownership

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed an amended Schedule 13G, revealing a combined beneficial ownership of 11.4% in Arbutus Biopharma Corp as of December 31, 2024.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Arbutus Biopharma Corp.
• As of December 31, 2024, Morgan Stanley beneficially owned an aggregate of 21,524,661 common shares, representing 11.4% of the class.
• Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley, beneficially owned 21,234,598 common shares, representing 11.2% of the class.
• The securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• Continued significant institutional ownership by a major financial institution like Morgan Stanley may signal confidence in Arbutus Biopharma Corp.
• The filing indicates a passive investment, suggesting no immediate intent to influence or control the company's operations.

Negatives

• The document itself does not contain any negative information; it is a routine disclosure of beneficial ownership.

Risks

• The document does not explicitly mention specific risks related to Arbutus Biopharma Corp's operations or financial health, as it is a disclosure of ownership, not a comprehensive company report.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Arbutus Biopharma Corp's future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing is a standard disclosure required when an institutional investor's beneficial ownership in a public company crosses certain thresholds. For the biopharma industry, significant institutional holdings can be a sign of investor interest in the company's pipeline or market position, although this specific filing does not provide details on the rationale behind the investment beyond it being in the ordinary course of business.

Comparison to Industry Standards

• This document does not provide financial or operational results that can be compared to industry standards or specific comparable companies/projects. It is a regulatory filing detailing beneficial ownership.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor perception and potentially liquidity.

Next Steps

• No specific future actions, events, or milestones for Arbutus Biopharma Corp are mentioned in this filing. The reporting persons will continue to file amendments as required by SEC rules.

Key Dates

Keywords

Arbutus Biopharma Corp, Morgan Stanley, Morgan Stanley Investment Management Inc., Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, Biopharma, SEC Filing